Efigenia Arias

Efigenia Arias

Auto-generated profile, based on publicly available information

Efigenia Arias

Gynecology Department, University Clinical Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
RPRaquel Piñeiro Pérez
Raquel Piñeiro Pérez
AVAna Vilar
Ana Vilar
EAEfigenia Arias
Efigenia Arias
VSVictoria Sampayo
Victoria Sampayo
AAAlicia Abalo-Piñeiro
Alicia Abalo-Piñeiro
LMLaura Muinelo
Laura Muinelo
Although the tumor immune microenvironment has been studied in endometrial cancer, the systemic immune alterations associated with disease progression and their potential prognostic significance remain poorly defined. In this study, peripheral blood immune subsets were characterized by multiparametric flow cytometry in 67 patients with EC and 20 healthy controls, including dendritic cells, MDSCs, T-cell subsets, NK cells, and exhaustion and senescence associated markers. Immune profiles were similar between healthy controls and patients with early-stage disease, whereas advanced tumors showed marked changes, including dendritic cell expansion, reduced CD4 + T-cell proportions, and increased frequencies of CD8 + CD27 - CD28 - and CD8 + CD57 + populations. Among clinicopathologic features, MDSC levels were associated with tumor grade and myometrial infiltration, while regulatory T cells were increased in TP53-mutated and microsatellite-stable tumors. In the advanced cohort (n=31), non-responders frequently displayed elevated CD8 + , CD8 + CD27 - CD28 - , and CD8 + CD57 + levels alongside decreased CD27 + CD28 + proportions. In multivariable Cox models, higher baseline CD8 + (HR 1.13), CD8 + CD27 - CD28 - (HR 1.04), and CD8 + CD57 + proportions (HR 1.07; all p<0.05) were independently associated with shorter PFS, whereas higher CD27 + CD28 + levels were associated with improved PFS. CD27 - CD28 - proportions were also linked to worse PFS by Kaplan-Meier analysis (HR 5.1, log-rank p=0.005). Longitudinal analysis (n=28) showed that senescent-like lymphocyte levels remained associated with progression across timepoints (OR 18.80), whereas total CD8 + proportions diverged progressively, reaching significance only from 6 months onward. Together, these findings identify systemic immune remodeling as a characteristic of advanced endometrial cancer and support the potential of circulating immune profiling for patient stratification and prognostic assessment, pending validation in larger prospective cohorts.

21 May 2024 in medRxiv
Verified
Preprint
Open access
PDF file
CCCarlos Casas-Arozamena
Carlos Casas-Arozamena
AVAna Vilar
Ana Vilar
JCJuan Cueva
Juan Cueva
EAEfigenia Arias
Efigenia Arias
VSVictoria Sampayo
Victoria Sampayo
LMLaura Muinelo
Laura Muinelo
Introduction In the past years, there has been a rise on advanced endometrial cancers (EC) patients resulting in mortality increase. To overcome this trend, it is essential to improve the stratification of the risk of post-surgery recurrence and to anticipate the development of disease relapse and resistance to treatment. Liquid biopsy analyses represent a promising tool to address these clinical challenges, however, the best strategy to efficiently apply them in the context of EC must be better defined. Therefore, the study was designed to determine the value of cfDNA/ctDNA monitoring to improve the clinical management of patients with localized and recurrent disease. Material & Methods Plasma samples and the uterine aspirate (UA) from 198 patients with EC were collected in different Spanish hospitals at surgery and throughout the course of the disease. The genetic landscape of UAs was characterized using targeted sequencing. Total cfDNA was isolated from all plasma samples, quantified, and analysed for the presence of ctDNA based on the mutational profile found on the UAs. Results The genetic characterization of UAs obtained at surgery allowed the identification of pathogenetic variants in the 95,45% of the tumours and ctDNA levels could be monitored in the 89,4% of the patients. High levels of cfDNA and detectable levels of ctDNA at baseline correlated with poor prognosis, for both DFS (p-value<0.0001; HR=9,25) and DSS (p-value<0.0001; HR=11,20). Importantly, this approach remains clinically significant when stratifying tumours based on histopathological risk factors, highlighting its additional value to identify patient with a poor evolution. In fact, cfDNA/ctDNA analysis served to identify patients who showed early post-surgery relapse. Moreover, longitudinal analyses of cfDNA/ctDNA proved to be a powerful asset to identify patients undergoing relapse, months prior to the arisen of any clinical evidence. Conclusion This study represents the most comprehensive study on cfDNA/ctDNA characterization in EC and demonstrates its value to improve the risk stratification and anticipate the disease relapse in patients with localized disease. Besides, the dynamic ctDNA assessment showed utility to complement the current strategies to monitor disease evolution and the response to treatment. Implementation of cfDNA/ctDNA monitoring into the clinical routine will provide an unique opportunity to improve EC management.

28 April 2026 in Molecular Oncology
Verified
Journal Article
Open access
CCCarlos Casas-Arozamena
Carlos Casas-Arozamena
KLKarin Teien Lande
Karin Teien Lande
EDEva Diaz
Eva Diaz
AVAna Vilar
Ana Vilar
JCJuan Cueva
Juan Cueva
LMLaura Muinelo
Laura Muinelo
Intratumor heterogeneity presents a major challenge in precision oncology for endometrial cancer (EC). Circulating tumor DNA (ctDNA) offers a minimally invasive method to monitor tumor evolution and therapeutic resistance. In this retrospective study, we evaluated a tumor‐agnostic NGS panel to detect and track ctDNA in 18 EC patients and directly compared its performance with a tumor‐informed ddPCR approach. ctDNA was detected by NGS in over 60% of plasma samples, while ddPCR showed higher positivity rates in paired samples (71.9% vs 62.5%), with overall concordance of 65.7% and fair agreement (Cohen's kappa = 0.23). The cfDNA‐NGS panel identified a broad spectrum of alterations, including relapse‐specific mutations indicative of clonal evolution, but showed lower sensitivity for low‐frequency variants compared with ddPCR. Discordant cases, including false‐negative results in both approaches, highlight the impact of assay sensitivity, target selection, and biological factors on ctDNA detection. ctDNA dynamics correlated with disease progression and treatment response, although detection was limited in cases with brain metastases. These findings support the utility of tumor‐agnostic ctDNA monitoring in advanced EC and highlight the importance of assay quality and careful interpretation to address limitations such as clonal hematopoiesis and technical sensitivity.

4 September 2026 in The Journal of Liquid Biopsy
Verified
Journal Article
Open access
RPRaquel Piñeiro Pérez
Raquel Piñeiro Pérez
AVAna Vilar
Ana Vilar
EAEfigenia Arias
Efigenia Arias
VSVictoria Sampayo
Victoria Sampayo
AAAlicia Abalo-Piñeiro
Alicia Abalo-Piñeiro
LMLaura Muinelo
Laura Muinelo